Is it one of your New Year’s Resolutions to participate in more clinical trials in 2025? Fantastic!!

We have an array of trials for you to choose from across the Pacific Northwest and we will continue to send out regular highlights throughout the year. If you have specific questions about clinical trials that might be appropriate for you, please reach out to our PNW Chapter Clinical Trial Education Volunteers, Laura Tremblay (LDTremblay71@gmail.com) and/or Jude Restis (jrestis@yahoo.com).

In this blog, we would like to highlight the trials currently enrolling or coming up soon at the Rainier Clinical Research Center (RCRC) in Renton, WA:

Sensor Studies

• Biolinq CGM: This study involves a 7-day wear period for up to 4 Biolinq sensors, along with one Libre sensor and one Dexcom G6 sensor. Participants will conduct fingersticks at home (8 per day) and will attend one 10-hour clinic visit during the study. Compensation is up to $930. Enrolling now!
• Dexcom CGM: This study involves a 15.5-day wear period for 4 Dexcom CGMs (2 on the back of the arm and 2 on the abdomen). Participants will conduct fingersticks at home (9 per day). There are no long in-clinic days for this study, only brief visits for sensor insertion and removal. Compensation is up to $715.

GLP-1/GIP Study

• Eli Lilly Tirzepatide (Mounjaro) Study: This study will examine tirzepatide (Mounjaro) versus placebo, with 20% of participants randomized to placebo for the 40-week treatment period and 80% of participants randomized to tirzepatide for the 40-week treatment period. Key inclusion criteria include BMI >25 and HbA1C 7.0-10.5%. For pump users, hybrid closed-loop systems (e.g. Tandem Control IQ, Medtronic Smart Guard, Omnipod 5) are permissible. Compensation will be provided, but the amount has not yet been shared. Screening will begin in April 2025.

Hypothyroid Study:

*This is not a type 1 diabetes study, per se. However, given hypothyroidism is an autoimmune disease, it often overlaps with type 1 diabetes.

• AbbVie Hypothyroidism Study: This study will evaluate the efficacy and safety of Armour Thyroid treatment compared with synthetic T4 (Synthroid) in subjects who have primary hypothyroidism. The study will include an 81-week treatment period with an additional 9 weeks of follow-up. Key inclusion criteria include continuous use of synthetic T4 (Synthroid) for at least 12 months with no dose changes within 3 months of the screening visit, dose of synthetic T4 of 25-200mcg at the screening visit, and BMI 18-40. Compensation is up to $2000. Enrolling now!

If you are interested in one or more of these trials, please contact the Site Coordinator at RCRC at recruitment@rainier-research.com or call 888-478-8343.